Determination of the functional hepatic reserve is still controversial. Many tests have been proposed, but the assay based on formation of the lidocaine metabolite, monoethylglycine xylidide, seems to offer a promising approach to this problem. In this study we evaluated the effectiveness of the monoethylglycine xylidide test in the clinical evaluation of 31 cirrhotic patients submitted to three different therapeutic options (sclerotherapy, transjugular intrahepatic portosystemic shunt and surgical procedures) and in 1 patient submitted to right hepatectomy for giant hepatic angioma. We found a statistically significant difference between Child A and C patients and between Child B and C patients. The test did not differentiate Child A from Child B patients. We found no correlation between the Child-Pugh score, serum bilirubin, albumin and prothrombin time. There were no differences among the three groups of patients that could be statistically related to their therapy. The monoethylglycine xylidide test seems to be an attractive alternative to previous methods for the evaluation of the functional hepatic reserve, but further studies are necessary to assess the prognostic value of the test in cirrhotics, to separate the independent contribution of portosystemic shunting and hepatocyte dysfunction to monoethylglycine xylidide formation, and to evaluate the test as a prognostic index in cirrhotic patients submitted to general surgery.
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Materials and Methods
Between January 1991 and September 1992 we performed the monoethylglycine xylidide test in 41 cirrhotic patients admitted to our surgical unit. Nine patients with monoethylglycine xylidide concentrations above 15 μπιοΐ/ΐ due to previous Hdocaine treatment were excluded from this study. One patient was affected by a giant hepatic angioma, and all the remaining patients suffered from histologically confirmed liver cirrhosis (tab. 1). Alcohol was the aetiology of liver cirrhosis in most cases (22 cases), 6 patients had posthepatitic cirrhosis, 2 had cryptogenic cirrhosis and 1 had biliary cirrhosis. Sixteen patients (50%) were referred to our department for bleeding gastrp-oesophageal varices (Group 1). In these patients bleeding was controlled by endoscopic sclerotherapy.
Eight patients (25%) (Group 2) were submitted to transjugular intrahepatic portosystemic shunt (see tab. 2) for bleeding recurrence from gastro-oesophageal varices (5 patients), ascites not responsive to medical therapy (2 patients), or reduction of portal hypertension in view of total oesophagectomy for oesophageal carcinoma (1 patient).
Eight patients (25%) (Group 3) were referred to us for surgical evaluation. Table 3 shows the patient group 3 with the diagnosis, the performed operation, the postoperative outcome and the follow-up.
All of the patients were submitted to the normal liver function tests and all of the 31 cirrhotic patients were classified according to Child-Pugh criteria (13): this classification includes ascites, encephalopathy, serum bilirubin, albumin and prothrombin time.
In the first group of patients, 4 were class A (Child-Pugh score ranging between 5 and 6), 7 were class Β (score between 7 and 9) and 5 were class C (score between 10 and 15).
In the second group, f 1 patient was Child A, 4 patients were Child Β and 3 patients were Child C.
In the third group, 1 patient was class A and 6 patients were class B.
In this latter group we enrolled a non-cirrhotic female receiving a right hepatectomy for giant hepatic angioma.
Venous blood samples for monoethylglycine xylidide determination were collected before and 15, 30 and 60 minutes after a single intravenous bolus of Hdocaine hydrochloride (1 mg/kg) injected over a period of 2-4 minutes. Monoethylglycine xylidide was determined in serum by the TDx fluorescence polarization immunoassay system (Abbott Laboratories, Chicago, IL, USA).
The significance of differences between groups was determined by one-way ANOVA, and groups of data were compared using the Snedecor F test.
Results
Monoethylglycine xylidide concentrations in all patients at 15, 30 and 60 minutes are shown in figure 1.
The monoethylglycine xylidide concentrations at 30 minutes in patient group 1 (sclerotherapy) ranged between < 6 μιηοΐ/l and 62 μιηοΐ/ΐ. In this group, monoethylglycine xylidide concentrations at 30 minutes ranged between 8 and 31 in Child-Pugh class A, between 7 and 62 in class 6 and between < 6 and 22 μιηοΐ/ΐ in class C. In group 2 transjugular intrahepatic portosystemic shunt the 30 minutes monoethylglyeine xylidide concentrations ranged between 6 and 62 μιηοΙ/1. Monoethylglyeine xylidide concentrations at 30 minutes, before the procedure, were 6 μιηοΐ/l in the single Child A patient, and they ranged between 18 and 62 in the class Β patients and between 6 and 17 μηιοΐ/ΐ in the class C patients. We compared these results with those obtained three months after the transjugular intrahepatic portosystemic shunt and found no significant differences in monoethylglyeine xylidide concentrations (t value = 1.07; ρ = 0.32). The results obtained in this group of patients are summarized in table 2.
In patient group 3 (operated) the monoethylglyeine xylidide concentrations at 30 minutes ranged between 2 and 23 μιηοΐ/ΐ for Child Β patients. The single Child A patient had a monoethylglyeine xylidide value of 86 μιηοΐ/ΐ. In the non-cirrhotic patient with giant hepatic angioma the 30 min monoethylglyeine xylidide concentration was 58 μπιοΙ/1. The results obtained in this third group of patients are summarized in table 3, where the outcome and the follow-up of single patients is also reported.
Discussion
The goal of this study was to investigate the effectiveness of the monoethylglyeine xylidide test in predicting the functional hepatic reserve in cirrhotic patients submitted to three different therapeutic options. We did not find any statistical difference in monoethylglyeine xylidide concentrations in the samples at 15, 30 and 60 minutes (see tab. 4); as also stated by other authors (1 -4), we think the monoethylglyeine xylidide determination at 30 minutes is sufficient for determination of the functional hepatic reserve in cirrhotic patients. We found a statistically significant difference between Child A and C patients and between Child Β arid C patients (F = 2.06; ρ < 0.05). On the basis of the monoethylglyeine xylidide we could not differentiate Child A from Child Β patients (mean values 29 μηιρί/ΐ for both), or find any correlation with the Child-Pugh score (see tab. 5). The monoethylglyeine xylidide test identified the Child C better than Child A or Β patients. In all the patients there was no statistical correlation between the monoethylglyeine xylidide concentrations at 30 minutes and the values of serum bilirubin, albumin and pro thrombin time. In table 5 the concentrations of bilirubin, albumin, prothrombin time and Pugh score are summarized with the statistical evaluation.
There were no statistical differences in monoethylglyeine xylidide values in the three groups of patients that could be statistically related to their therapy. Moreover, in the second group of patients, we evaluated the 30 minutes monoethylglycine xylidide concentrations before and three months after transjugulaf intrahepatic portosystemic shunt, i.e. from a haemodynamic point of view, a side-to-side portocaval shunt; the monoethylglycine xylidide concentrations ranged between 6 and 62 μιηοΐ/l before transjugular intrahepatic portosystemic shunt and between 10 and 32 after transjugular intrahepatic portosystemic shunt. From literature data (1, 3), we know that in hepatic cirrhosis the formation of monoethylglycine xylidide is decreased by both portosystemic shunting and hepatocyte dysfunction, but we were not able to differentiate the independent contribution of portosystemic shunting and impaired hepatocyte activity.
Of all the 32 patients, 4 died during a follow-up period ranging from 2 to 19 months. One of these died of cancerous cachexia, the other 3 of liver failure; these 3 patients had 30 min irioiioethylglycine xylidide concentrations < 8 μηιοΐ/ΐ, but the patient number is too small for a statistically relevant prognostic conclusion.
In conclusion, the monoethylglycine xylidide test is quick and easy to perform, it does not require serial blood sample collection but only two specimens of about 1 ml, monoethylglycine xylidide concentrations can be measured within 20 minutes, and the low doses of lidocaine used appear to be safe (1, 5) . The monoethylglycine xylidide liver function test seems to be a promising approach to the evaluation of the functional hepatic reserve in cirrhotic patients. Another interesting use of the monoethylglycine xylidide test could be the preoperative assessment of cirrhotic patients prior to general surgery. A larger number of Further prospective studies are necessary to fully assess the prognostic value of the test in cirrhotics and to separate the independent contribution of portosystemic shunting and hepatocyte dysfunction in monoethylglycine xylidide formation. It may then be possible to use the test as a predictor of mortality and morbidity, and to assess the extent of intra-and extrahepatic shunting in cirrhotic patients.
